



## Clinical trial results:

### A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin's lymphoma (iNHL) - CHRONOS-2

#### Summary

EudraCT number	2014-000925-19
Trial protocol	AT IE GR PL IT
Global end of trial date	26 October 2022

#### Results information

Result version number	v1 (current)
This version publication date	20 October 2023
First version publication date	20 October 2023

#### Trial information

##### Trial identification

Sponsor protocol code	BAY80-6946 / 17322
-----------------------	--------------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02369016
WHO universal trial number (UTN)	-

Notes:

##### Sponsors

Sponsor organisation name	Bayer AG
Sponsor organisation address	Kaiser Wilhelm Allee, Leverkusen, Germany, D-51368
Public contact	Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com
Scientific contact	Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	15 December 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	26 October 2022
Global end of trial reached?	Yes
Global end of trial date	26 October 2022
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To assess the safety of copanlisib.

Protection of trial subjects:

The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the International Conference on Harmonization guideline E6: Good Clinical Practice. Before entering the study, the informed consent form was read by and explained to all subjects. Participating subjects signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	22 September 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Brazil: 1
Country: Number of subjects enrolled	Bulgaria: 1
Country: Number of subjects enrolled	Greece: 2
Country: Number of subjects enrolled	Italy: 1
Country: Number of subjects enrolled	Poland: 3
Country: Number of subjects enrolled	Russian Federation: 7
Country: Number of subjects enrolled	Korea, Republic of: 6
Country: Number of subjects enrolled	Taiwan: 2
Country: Number of subjects enrolled	Turkey: 2
Worldwide total number of subjects	25
EEA total number of subjects	7

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	17
From 65 to 84 years	8
85 years and over	0

---

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted at 20 study centers in 10 countries/regions: Brazil (2), Bulgaria (1), Greece (1), Italy (2), Poland (1), Russian Federation (5), South Africa (1), South Korea (5), Taiwan (1) and Turkey (1) between 22 September 2015 (first patient first visit) and 26 October 2022 (last patient last visit).

### Pre-assignment

Screening details:

34 participants were screened. 9 participants were screening failures and 25 participants were randomized to study treatment: 17 to copanlisib and 8 to placebo. All randomized participants also received at least one dose of study treatment and were valid for safety analyses. After study unblinding 7 placebo participants switched to copanlisib.

### Period 1

Period 1 title	overall (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Copanlisib (BAY80-6946, Aliqopa)

Arm description:

Participants who were randomized to copanlisib until end of the study

Arm type	Experimental
Investigational medicinal product name	Copanlisib 60 mg solution for infusion
Investigational medicinal product code	BAY80-6946
Other name	Aliqopa
Pharmaceutical forms	Solution for infusion
Routes of administration	Infusion

Dosage and administration details:

Copanlisib was administered IV over approximately 1 h on Days 1, 8, and 15 of each 28-day treatment cycle (3 weeks on/1 week off).

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Participants who were randomized to placebo until switching from placebo to copanlisib after disease progression or after study unblinding

Arm type	Experimental
Investigational medicinal product name	placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Placebo was administered IV over approximately 1 h on Days 1, 8, and 15 of each 28-day treatment cycle (3 weeks on/1 week off).

<b>Number of subjects in period 1</b>	Copanlisib (BAY80-6946, Aliqopa)	Placebo
Started	17	8
Completed	0	0
Not completed	17	8
AE associated with clinical disease progression	2	1
AE not associated with clinical disease progression	4	1
Progressive disease - clinical progression	1	4
withdrawal by patient	4	-
Progressive disease - radiological progression	6	2

## Baseline characteristics

### Reporting groups

Reporting group title	overall
-----------------------	---------

Reporting group description: -

Reporting group values	overall	Total	
Number of subjects	25	25	
Age categorical Units: Subjects			
Adults (18-64 years)	17	17	
From 65-84 years	8	8	
Gender categorical Units: Subjects			
Female	8	8	
Male	17	17	

### Subject analysis sets

Subject analysis set title	Safety analysis set
----------------------------	---------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

All participants with at least one administration of the study drug were included in the Safety analysis set.

Subject analysis set title	Full analysis set
----------------------------	-------------------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

All participants who were randomized to the treatment arms at the start of the study were included in the FAS.

Subject analysis set title	Switched to copanlisib
----------------------------	------------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

Participants who switched from placebo to copanlisib

Subject analysis set title	Treated with copanlisib
----------------------------	-------------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

Participants who were treated with copanlisib (randomized to copanlisib + switched from placebo to copanlisib)

Reporting group values	Safety analysis set	Full analysis set	Switched to copanlisib
Number of subjects	25	25	7
Age categorical Units: Subjects			
Adults (18-64 years)	17	17	4
From 65-84 years	8	8	3
Gender categorical Units: Subjects			
Female	8	8	1
Male	17	17	6

<b>Reporting group values</b>	Treated with copanlisib		
Number of subjects	24		
Age categorical Units: Subjects			
Adults (18-64 years)	16		
From 65-84 years	8		
Gender categorical Units: Subjects			
Female	8		
Male	16		

## End points

### End points reporting groups

Reporting group title	Copanlisib (BAY80-6946, Aliqopa)
Reporting group description: Participants who were randomized to copanlisib until end of the study	
Reporting group title	Placebo
Reporting group description: Participants who were randomized to placebo until switching from placebo to copanlisib after disease progression or after study unblinding	
Subject analysis set title	Safety analysis set
Subject analysis set type	Safety analysis
Subject analysis set description: All participants with at least one administration of the study drug were included in the Safety analysis set.	
Subject analysis set title	Full analysis set
Subject analysis set type	Full analysis
Subject analysis set description: All participants who were randomized to the treatment arms at the start of the study were included in the FAS.	
Subject analysis set title	Switched to copanlisib
Subject analysis set type	Sub-group analysis
Subject analysis set description: Participants who switched from placebo to copanlisib	
Subject analysis set title	Treated with copanlisib
Subject analysis set type	Sub-group analysis
Subject analysis set description: Participants who were treated with copanlisib (randomized to copanlisib + switched from placebo to copanlisib)	

### Primary: Number of participants with treatment-emergent adverse events (TEAE)s

End point title	Number of participants with treatment-emergent adverse events (TEAE)s <sup>[1]</sup>
End point description: Adverse event data were collected after signing the informed consent until 30 days after the last study drug administration (end of safety follow-up)	
End point type	Primary
End point timeframe: up to 7 years	

#### Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due the limited number of patients, statistical analyses included in this study focused on descriptive statistics only.

Due to the short duration of placebo treatment before switching to copanlisib and the small number of patients receiving placebo, any comparisons between copanlisib and placebo treatment are not considered meaningful.

End point values	Copanlisib (BAY80-6946, Aliqopa)	Placebo	Switched to copanlisib	Treated with copanlisib
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	17	8	7	24
Units: patients	17	7	7	24

### Statistical analyses

No statistical analyses for this end point

### Primary: Number of participants with treatment-emergent serious adverse events

End point title	Number of participants with treatment-emergent serious adverse events <sup>[2]</sup>
-----------------	--

End point description:

Serious Adverse event data were collected after signing the informed consent until 30 days after the last study drug administration (end of safety follow-up)

End point type	Primary
----------------	---------

End point timeframe:

up to 7 years

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due the limited number of patients, statistical analyses included in this study focused on descriptive statistics only.

Due to the short duration of placebo treatment before switching to copanlisib and the small number of patients receiving placebo, any comparisons between copanlisib and placebo treatment are not considered meaningful.

End point values	Copanlisib (BAY80-6946, Aliqopa)	Placebo	Switched to copanlisib	Treated with copanlisib
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	17	8	7	24
Units: patients	6	1	5	11

### Statistical analyses

No statistical analyses for this end point

### Primary: Participants with abnormal laboratory parameters

End point title	Participants with abnormal laboratory parameters <sup>[3]</sup>
-----------------	---

End point description:

- Above threshold 10% and reported as TEAEs - - any event grade 1-4 -

End point type	Primary
----------------	---------

End point timeframe:

up to 7 years

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due the limited number of patients, statistical analyses included in this study focused on descriptive statistics only.

Due to the short duration of placebo treatment before switching to copanlisib and the small number of patients receiving placebo, any comparisons between copanlisib and placebo treatment are not considered meaningful.

End point values	Copanlisib (BAY80-6946, Aliqopa)	Placebo	Switched to copanlisib	Treated with copanlisib
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	17	8	7	24
Units: patients				
ANY	9	1	3	12
Hyperglycaemia	6	0	4	10
Neutropenia	6	0	1	7
Neutrophil count decreased	4	0	2	6
Anaemia	2	2	4	6
Platelet count decreased	3	0	2	5

## Statistical analyses

No statistical analyses for this end point

### Primary: Participants with abnormal vital signs

End point title	Participants with abnormal vital signs <sup>[4]</sup>
End point description:	- Reported as TEAEs - worst CTCAE grade 'total' -
End point type	Primary
End point timeframe:	up to 7 years

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Due the limited number of patients, statistical analyses included in this study focused on descriptive statistics only.

Due to the short duration of placebo treatment before switching to copanlisib and the small number of patients receiving placebo, any comparisons between copanlisib and placebo treatment are not considered meaningful.

End point values	Copanlisib (BAY80-6946, Aliqopa)	Placebo	Switched to copanlisib	Treated with copanlisib
Subject group type	Reporting group	Reporting group	Subject analysis set	Subject analysis set
Number of subjects analysed	17	8	7	24
Units: patients				
Blood pressure increased	2	0	1	3
Electrocardiogram QT prolonged	1	0	0	1

## **Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

from the start of study drug administration until 30 days after the last study drug administration, up to end of safety follow-up, approximately 7 years

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25.1
--------------------	------

### Reporting groups

Reporting group title	Randomized to copanlisib
-----------------------	--------------------------

Reporting group description:

Participants who were randomized to copanlisib and continued copanlisib treatment after study unblinding (randomized to copanlisib group)

Reporting group title	Randomized to placebo
-----------------------	-----------------------

Reporting group description:

Participants who were randomized to placebo until switching from placebo to copanlisib after disease progression or after study unblinding

Reporting group title	Switched to copanlisib
-----------------------	------------------------

Reporting group description:

Participants who switched from placebo to copanlisib

Reporting group title	Treated with copanlisib
-----------------------	-------------------------

Reporting group description:

Participants who were treated with copanlisib (randomized to copanlisib + switched from placebo to copanlisib)

<b>Serious adverse events</b>	Randomized to copanlisib	Randomized to placebo	Switched to copanlisib
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 17 (35.29%)	1 / 8 (12.50%)	5 / 7 (71.43%)
number of deaths (all causes)	2	1	2
number of deaths resulting from adverse events	0	0	2
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alanine aminotransferase increased			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration			

site conditions			
General physical health deterioration			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 17 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Skin and subcutaneous tissue disorders			
Skin ulcer			
subjects affected / exposed	0 / 17 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	2 / 7 (28.57%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella bacteraemia			
subjects affected / exposed	0 / 17 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pneumocystis jirovecii pneumonia			

subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
Hyperglycaemic hyperosmolar nonketotic syndrome			
subjects affected / exposed	0 / 17 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Treated with copanlisib		
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	11 / 24 (45.83%)		
number of deaths (all causes)	4		
number of deaths resulting from adverse events	2		
<b>Investigations</b>			
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Alanine aminotransferase increased			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>General disorders and administration site conditions</b>			
General physical health deterioration			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Gastrointestinal disorders</b>			
Diarrhoea			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
<b>Respiratory, thoracic and mediastinal disorders</b>			

Dyspnoea			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Skin and subcutaneous tissue disorders			
Skin ulcer			
subjects affected / exposed	0 / 24 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Cellulitis			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	3 / 24 (12.50%)		
occurrences causally related to treatment / all	1 / 4		
deaths causally related to treatment / all	0 / 0		
Klebsiella bacteraemia			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hyperglycaemic hyperosmolar nonketotic syndrome			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Randomized to copanlisib	Randomized to placebo	Switched to copanlisib
Total subjects affected by non-serious adverse events subjects affected / exposed	17 / 17 (100.00%)	7 / 8 (87.50%)	7 / 7 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Seborrhoeic keratosis subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 8 (12.50%) 1	0 / 7 (0.00%) 0
Cancer pain subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	3 / 17 (17.65%) 32	1 / 8 (12.50%) 1	2 / 7 (28.57%) 19
Surgical and medical procedures Tooth extraction subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
General disorders and administration site conditions Extravasation subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Asthenia subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 8 (12.50%) 1	1 / 7 (14.29%) 2
Fatigue subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 3	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
Pain subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
Injection site irritation subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Pyrexia			

subjects affected / exposed occurrences (all)	2 / 17 (11.76%) 6	0 / 8 (0.00%) 0	3 / 7 (42.86%) 4
General physical health deterioration subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Non-cardiac chest pain subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
Immune system disorders			
Hypersensitivity subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Immunodeficiency common variable subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	3 / 17 (17.65%) 3	1 / 8 (12.50%) 1	2 / 7 (28.57%) 4
Catarrh subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Upper-airway cough syndrome subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Organising pneumonia subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Sinus pain subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
Rhinorrhoea subjects affected / exposed occurrences (all)	2 / 17 (11.76%) 2	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Productive cough			

subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 5	2 / 8 (25.00%) 3	1 / 7 (14.29%) 1
Lung disorder subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
Dyspnoea subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	2 / 7 (28.57%) 2
Psychiatric disorders			
Depressed mood subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Restlessness subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Insomnia subjects affected / exposed occurrences (all)	2 / 17 (11.76%) 2	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
Investigations			
Blood bilirubin increased subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Blood creatinine increased subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Blood pressure increased subjects affected / exposed occurrences (all)	2 / 17 (11.76%) 12	0 / 8 (0.00%) 0	1 / 7 (14.29%) 7
Electrocardiogram QT prolonged subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Platelet count decreased subjects affected / exposed occurrences (all)	3 / 17 (17.65%) 5	0 / 8 (0.00%) 0	2 / 7 (28.57%) 4
Neutrophil count decreased			

subjects affected / exposed	4 / 17 (23.53%)	0 / 8 (0.00%)	2 / 7 (28.57%)
occurrences (all)	9	0	4
N-terminal prohormone brain natriuretic peptide increased			
subjects affected / exposed	0 / 17 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 17 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Cytomegalovirus test positive			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Weight increased			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Weight decreased			
subjects affected / exposed	2 / 17 (11.76%)	1 / 8 (12.50%)	1 / 7 (14.29%)
occurrences (all)	4	1	1
Lipase increased			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Injury, poisoning and procedural complications			
Arthropod bite			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Accidental overdose			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Cervical vertebral fracture			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Lumbar vertebral fracture			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Thoracic vertebral fracture			

subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Limb injury subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
Cardiac disorders Tachycardia subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 8 (12.50%) 6	1 / 7 (14.29%) 3
Nervous system disorders Headache subjects affected / exposed occurrences (all)	3 / 17 (17.65%) 5	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
Dizziness subjects affected / exposed occurrences (all)	3 / 17 (17.65%) 8	1 / 8 (12.50%) 1	0 / 7 (0.00%) 0
Ataxia subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 8 (12.50%) 1	0 / 7 (0.00%) 0
Muscle contractions involuntary subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Paraesthesia subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 4	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Somnolence subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
Neuralgia subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Tremor subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Blood and lymphatic system disorders			

Neutropenia			
subjects affected / exposed	6 / 17 (35.29%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	14	0	4
Thrombocytopenia			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	2 / 7 (28.57%)
occurrences (all)	1	0	2
Lymphopenia			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	11	0	0
Anaemia			
subjects affected / exposed	2 / 17 (11.76%)	2 / 8 (25.00%)	4 / 7 (57.14%)
occurrences (all)	2	2	11
Hyperviscosity syndrome			
subjects affected / exposed	1 / 17 (5.88%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	1	1	0
Ear and labyrinth disorders			
External ear inflammation			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Eye disorders			
Conjunctivitis allergic			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Conjunctival hyperaemia			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Lacrimation increased			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 17 (5.88%)	1 / 8 (12.50%)	1 / 7 (14.29%)
occurrences (all)	1	1	1
Abdominal pain			
subjects affected / exposed	2 / 17 (11.76%)	2 / 8 (25.00%)	0 / 7 (0.00%)
occurrences (all)	2	2	0
Abdominal pain upper			

subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Anal fissure			
subjects affected / exposed	0 / 17 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Constipation			
subjects affected / exposed	0 / 17 (0.00%)	2 / 8 (25.00%)	0 / 7 (0.00%)
occurrences (all)	0	2	0
Dental caries			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Diarrhoea			
subjects affected / exposed	3 / 17 (17.65%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	12	0	6
Dyspepsia			
subjects affected / exposed	0 / 17 (0.00%)	0 / 8 (0.00%)	2 / 7 (28.57%)
occurrences (all)	0	0	2
Gastric ulcer			
subjects affected / exposed	2 / 17 (11.76%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Gastritis			
subjects affected / exposed	0 / 17 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Gastrointestinal pain			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Gingival pain			
subjects affected / exposed	2 / 17 (11.76%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	2	0	1
Haemorrhoids			
subjects affected / exposed	0 / 17 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Mouth ulceration			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
Stomatitis			

subjects affected / exposed occurrences (all)	3 / 17 (17.65%) 5	0 / 8 (0.00%) 0	2 / 7 (28.57%) 2
Proctalgia subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	2 / 17 (11.76%) 6	1 / 8 (12.50%) 1	0 / 7 (0.00%) 0
Hepatobiliary disorders Hepatotoxicity subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
Skin and subcutaneous tissue disorders Dermatitis subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
Rash subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
Pruritus subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	1 / 8 (12.50%) 1	0 / 7 (0.00%) 0
Palmar-plantar erythrodysesthesia syndrome subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Dry skin subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Dermatitis bullous subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Dermatitis atopic subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Paraneoplastic rash			

subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Urticaria subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 3	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Skin ulcer subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 8 (12.50%) 1	1 / 7 (14.29%) 1
Skin reaction subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Rash maculo-papular subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Renal and urinary disorders Renal colic subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Musculoskeletal and connective tissue disorders Bone pain subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Arthralgia subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	1 / 8 (12.50%) 1	1 / 7 (14.29%) 1
Joint contracture subjects affected / exposed occurrences (all)	0 / 17 (0.00%) 0	0 / 8 (0.00%) 0	1 / 7 (14.29%) 1
Muscular weakness subjects affected / exposed occurrences (all)	1 / 17 (5.88%) 1	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	2 / 17 (11.76%) 3	0 / 8 (0.00%) 0	0 / 7 (0.00%) 0
Musculoskeletal chest pain			

subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Musculoskeletal stiffness			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
<b>Infections and infestations</b>			
<b>Bronchitis</b>			
subjects affected / exposed	0 / 17 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
<b>Cellulitis</b>			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
<b>Clostridium difficile colitis</b>			
subjects affected / exposed	0 / 17 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
<b>Conjunctivitis</b>			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
<b>Herpes zoster</b>			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	1	0	1
<b>Herpes simplex</b>			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
<b>Nasopharyngitis</b>			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
<b>Pneumonia</b>			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	2 / 7 (28.57%)
occurrences (all)	1	0	2
<b>Periodontitis</b>			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
<b>Scrub typhus</b>			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0

Sinusitis			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	3	0	2
Upper respiratory tract infection			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	3 / 7 (42.86%)
occurrences (all)	1	0	4
Urinary tract infection			
subjects affected / exposed	3 / 17 (17.65%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	3	1	0
Oral infection			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Respiratory tract infection viral			
subjects affected / exposed	0 / 17 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Alveolar osteitis			
subjects affected / exposed	0 / 17 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Herpes zoster reactivation			
subjects affected / exposed	0 / 17 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			
Hyperuricaemia			
subjects affected / exposed	2 / 17 (11.76%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	3	1	0
Hypermagnesaemia			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0
Hyperglycaemia			
subjects affected / exposed	6 / 17 (35.29%)	0 / 8 (0.00%)	4 / 7 (57.14%)
occurrences (all)	107	0	59
Hypercholesterolaemia			

subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	2	0	0
<b>Hypercalcaemia</b>			
subjects affected / exposed	0 / 17 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
<b>Cachexia</b>			
subjects affected / exposed	0 / 17 (0.00%)	1 / 8 (12.50%)	0 / 7 (0.00%)
occurrences (all)	0	1	0
<b>Hypocalcaemia</b>			
subjects affected / exposed	0 / 17 (0.00%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	0	0	1
<b>Hypophosphataemia</b>			
subjects affected / exposed	0 / 17 (0.00%)	1 / 8 (12.50%)	2 / 7 (28.57%)
occurrences (all)	0	1	3
<b>Hypomagnesaemia</b>			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	1 / 7 (14.29%)
occurrences (all)	2	0	1
<b>Hypokalaemia</b>			
subjects affected / exposed	0 / 17 (0.00%)	0 / 8 (0.00%)	2 / 7 (28.57%)
occurrences (all)	0	0	3
<b>Lactic acidosis</b>			
subjects affected / exposed	0 / 17 (0.00%)	1 / 8 (12.50%)	1 / 7 (14.29%)
occurrences (all)	0	1	1
<b>Decreased appetite</b>			
subjects affected / exposed	2 / 17 (11.76%)	1 / 8 (12.50%)	1 / 7 (14.29%)
occurrences (all)	2	1	1
<b>Dyslipidaemia</b>			
subjects affected / exposed	1 / 17 (5.88%)	0 / 8 (0.00%)	0 / 7 (0.00%)
occurrences (all)	1	0	0

<b>Non-serious adverse events</b>	Treated with copanlisib		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	24 / 24 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Seborrhoeic keratosis subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0		
Cancer pain subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	5 / 24 (20.83%) 51		
Surgical and medical procedures Tooth extraction subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
General disorders and administration site conditions Extravasation subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Asthenia subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 2		
Fatigue subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 4		
Pain subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Injection site irritation subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Pyrexia subjects affected / exposed occurrences (all)	5 / 24 (20.83%) 10		
General physical health deterioration subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		

Non-cardiac chest pain subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Immunodeficiency common variable subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	5 / 24 (20.83%) 7		
Catarrh subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Upper-airway cough syndrome subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Organising pneumonia subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Sinus pain subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Rhinorrhoea subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 2		
Productive cough subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 6		
Lung disorder subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Dyspnoea			

subjects affected / exposed occurrences (all)	3 / 24 (12.50%) 3		
Psychiatric disorders			
Depressed mood subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Restlessness subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Insomnia subjects affected / exposed occurrences (all)	3 / 24 (12.50%) 3		
Investigations			
Blood bilirubin increased subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Blood creatinine increased subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Blood pressure increased subjects affected / exposed occurrences (all)	3 / 24 (12.50%) 19		
Electrocardiogram QT prolonged subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Platelet count decreased subjects affected / exposed occurrences (all)	5 / 24 (20.83%) 9		
Neutrophil count decreased subjects affected / exposed occurrences (all)	6 / 24 (25.00%) 13		
N-terminal prohormone brain natriuretic peptide increased subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Blood alkaline phosphatase increased			

subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Cytomegalovirus test positive subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Weight increased subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Weight decreased subjects affected / exposed occurrences (all)	3 / 24 (12.50%) 5		
Lipase increased subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Injury, poisoning and procedural complications			
Arthropod bite subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 2		
Accidental overdose subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Cervical vertebral fracture subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Lumbar vertebral fracture subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Thoracic vertebral fracture subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Limb injury subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Cardiac disorders			

Tachycardia subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 3		
Nervous system disorders			
Headache subjects affected / exposed occurrences (all)	4 / 24 (16.67%) 6		
Dizziness subjects affected / exposed occurrences (all)	3 / 24 (12.50%) 8		
Ataxia subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0		
Muscle contractions involuntary subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Paraesthesia subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 4		
Somnolence subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 2		
Neuralgia subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Tremor subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Blood and lymphatic system disorders			
Neutropenia subjects affected / exposed occurrences (all)	7 / 24 (29.17%) 18		
Thrombocytopenia subjects affected / exposed occurrences (all)	3 / 24 (12.50%) 3		
Lymphopenia			

<p>subjects affected / exposed occurrences (all)</p> <p>Anaemia subjects affected / exposed occurrences (all)</p> <p>Hyperviscosity syndrome subjects affected / exposed occurrences (all)</p>	<p>1 / 24 (4.17%) 11</p> <p>6 / 24 (25.00%) 13</p> <p>1 / 24 (4.17%) 1</p>		
<p>Ear and labyrinth disorders External ear inflammation subjects affected / exposed occurrences (all)</p>	<p>1 / 24 (4.17%) 1</p>		
<p>Eye disorders Conjunctivitis allergic subjects affected / exposed occurrences (all)</p> <p>Conjunctival hyperaemia subjects affected / exposed occurrences (all)</p> <p>Lacrimation increased subjects affected / exposed occurrences (all)</p>	<p>1 / 24 (4.17%) 2</p> <p>1 / 24 (4.17%) 1</p> <p>1 / 24 (4.17%) 1</p>		
<p>Gastrointestinal disorders Abdominal discomfort subjects affected / exposed occurrences (all)</p> <p>Abdominal pain subjects affected / exposed occurrences (all)</p> <p>Abdominal pain upper subjects affected / exposed occurrences (all)</p> <p>Anal fissure subjects affected / exposed occurrences (all)</p> <p>Constipation</p>	<p>2 / 24 (8.33%) 2</p> <p>2 / 24 (8.33%) 2</p> <p>1 / 24 (4.17%) 1</p> <p>1 / 24 (4.17%) 1</p>		

subjects affected / exposed	0 / 24 (0.00%)		
occurrences (all)	0		
Dental caries			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Diarrhoea			
subjects affected / exposed	4 / 24 (16.67%)		
occurrences (all)	18		
Dyspepsia			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Gastric ulcer			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Gastritis			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Gastrointestinal pain			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Gingival pain			
subjects affected / exposed	3 / 24 (12.50%)		
occurrences (all)	3		
Haemorrhoids			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Mouth ulceration			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	2		
Stomatitis			
subjects affected / exposed	5 / 24 (20.83%)		
occurrences (all)	7		
Proctalgia			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Nausea			

subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 6		
Hepatobiliary disorders Hepatotoxicity subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Skin and subcutaneous tissue disorders Dermatitis subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Rash subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Pruritus subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Palmar-plantar erythrodysesthesia syndrome subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Dry skin subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Dermatitis bullous subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Dermatitis atopic subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Paraneoplastic rash subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Urticaria subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 3		
Skin ulcer			

<p>subjects affected / exposed occurrences (all)</p> <p>Skin reaction subjects affected / exposed occurrences (all)</p> <p>Rash maculo-papular subjects affected / exposed occurrences (all)</p>	<p>1 / 24 (4.17%) 1</p> <p>1 / 24 (4.17%) 1</p> <p>1 / 24 (4.17%) 1</p>		
<p>Renal and urinary disorders Renal colic subjects affected / exposed occurrences (all)</p>	<p>1 / 24 (4.17%) 1</p>		
<p>Musculoskeletal and connective tissue disorders</p> <p>Bone pain subjects affected / exposed occurrences (all)</p> <p>Arthralgia subjects affected / exposed occurrences (all)</p> <p>Joint contracture subjects affected / exposed occurrences (all)</p> <p>Muscular weakness subjects affected / exposed occurrences (all)</p> <p>Myalgia subjects affected / exposed occurrences (all)</p> <p>Musculoskeletal chest pain subjects affected / exposed occurrences (all)</p> <p>Musculoskeletal stiffness subjects affected / exposed occurrences (all)</p>	<p>1 / 24 (4.17%) 1</p> <p>1 / 24 (4.17%) 1</p> <p>1 / 24 (4.17%) 1</p> <p>1 / 24 (4.17%) 1</p> <p>2 / 24 (8.33%) 3</p> <p>1 / 24 (4.17%) 1</p> <p>1 / 24 (4.17%) 2</p>		
<p>Infections and infestations</p>			

Bronchitis			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Cellulitis			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Clostridium difficile colitis			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Conjunctivitis			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Herpes zoster			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	2		
Herpes simplex			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Nasopharyngitis			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Pneumonia			
subjects affected / exposed	3 / 24 (12.50%)		
occurrences (all)	3		
Periodontitis			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Scrub typhus			
subjects affected / exposed	1 / 24 (4.17%)		
occurrences (all)	1		
Sinusitis			
subjects affected / exposed	2 / 24 (8.33%)		
occurrences (all)	5		
Upper respiratory tract infection			
subjects affected / exposed	4 / 24 (16.67%)		
occurrences (all)	5		

Urinary tract infection subjects affected / exposed occurrences (all)	3 / 24 (12.50%) 3		
Oral infection subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Respiratory tract infection viral subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Alveolar osteitis subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Pneumocystis jirovecii pneumonia subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Herpes zoster reactivation subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Metabolism and nutrition disorders			
Hyperuricaemia subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 3		
Hypermagnesaemia subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Hyperglycaemia subjects affected / exposed occurrences (all)	10 / 24 (41.67%) 166		
Hypercholesterolaemia subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 2		
Hypercalcaemia subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Cachexia			

subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0		
Hypocalcaemia subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Hypophosphataemia subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 3		
Hypomagnesaemia subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 3		
Hypokalaemia subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 3		
Lactic acidosis subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		
Decreased appetite subjects affected / exposed occurrences (all)	3 / 24 (12.50%) 3		
Dyslipidaemia subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
25 November 2014	<ul style="list-style-type: none"><li>• Several inclusion/exclusion and withdrawal criteria were modified.</li><li>• The study target population for efficacy analysis was changed from iNHL to FL patients.</li><li>• Randomization ratio was changed from 1:1 to 2:1 and prior treatment with PI3K inhibitors was added as a new stratification factor.</li><li>• Time to improvement in disease-related symptoms physical (subscale) (DRS-P) and secondary PFS (PFS2) were added as efficacy variables.</li></ul>
16 February 2016	<ul style="list-style-type: none"><li>• Several inclusion/exclusion criteria were modified.</li><li>• Guidance for the management of noninfectious pneumonitis (NIP), glucose and BP increases were updated.</li></ul>
21 July 2016	<ul style="list-style-type: none"><li>• Several inclusion/exclusion criteria were modified.</li><li>• Withdrawal criteria of study treatment due to cytomegalovirus (CMV) infection was added.</li><li>• Guidance for monitoring and prophylaxis of opportunistic infections was added.</li></ul>
31 March 2017	<p>Changes were made following the sponsor's decision to stop enrollment due to a lack of feasibility to complete this study in a reasonable time frame:</p> <ul style="list-style-type: none"><li>• Study design was modified from a randomized, double-blind, placebo-controlled study to an open-label, single arm study.</li><li>• Statistical analyses and efficacy endpoints were revised. Primary efficacy endpoint was changed from PFS to objective response rate and several secondary efficacy endpoints were removed.</li><li>• Central imaging review was removed, and bone marrow biopsy was changed to local standard of care.</li></ul>
01 December 2017	<p>The study design was further modified due to the limited number of participants to be included in the analyses:</p> <ul style="list-style-type: none"><li>• Primary endpoint was changed to safety and other study objectives were removed.</li><li>• Active and survival follow-up periods were removed.</li><li>• Several withdrawal criteria were modified.</li><li>• Timing of statistical analysis and guidance for tumor assessments were changed.</li></ul>

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported